Single dose escalation studies with inhaled POL6014, a potent novel selective reversible inhibitor of human neutrophil elastase, in healthy volunteers and subjects with cystic fibrosis

• Published in: Journal of cystic fibrosis Vol. 19; no. 2; pp. 299 - 304
• Main Authors: Barth, P., Bruijnzeel, P., Wach, A., Sellier Kessler, O., Hooftman, L., Zimmermann, J., Naue, N., Huber, B., Heimbeck, I., Kappeler, D., Timmer, W., Chevalier, E.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.03.2020
• Subjects: Cystic fibrosis; Inflammation; Inhalation; Neutrophil elastase inhibitor; Pharmacokinetics; Pulmonary/Respiratory; Safety; Cystic fibrosis; Inflammation; Safety; Pharmacokinetics; Neutrophil elastase inhibitor; Inhalation

POL6014 is a novel, orally inhaled neutrophil elastase (NE) inhibitor in development for cystic fibrosis (CF). Two studies, one in healthy volunteers (HVs, doses 20 to 960 mg) and one in subjects with CF (doses 80 to 320 mg) were conducted to evaluate the safety, tolerability and pharmacokinetics (P...